Cloughesy, Timothy F. http://orcid.org/0000-0002-8656-7483
Mochizuki, Aaron Y. http://orcid.org/0000-0003-1073-916X
Orpilla, Joey R. http://orcid.org/0000-0002-6679-9463
Hugo, Willy http://orcid.org/0000-0002-1426-7190
Lee, Alexander H. http://orcid.org/0000-0002-4583-0740
Davidson, Tom B.
Wang, Anthony C.
Ellingson, Benjamin M.
Rytlewski, Julie A. http://orcid.org/0000-0001-5244-6790
Sanders, Catherine M.
Kawaguchi, Eric S.
Du, Lin
Li, Gang
Yong, William H.
Gaffey, Sarah C.
Cohen, Adam L. http://orcid.org/0000-0002-8541-2287
Mellinghoff, Ingo K.
Lee, Eudocia Q.
Reardon, David A.
O’Brien, Barbara J.
Butowski, Nicholas A.
Nghiemphu, Phioanh L.
Clarke, Jennifer L.
Arrillaga-Romany, Isabel C.
Colman, Howard
Kaley, Thomas J.
de Groot, John F.
Liau, Linda M.
Wen, Patrick Y.
Prins, Robert M. http://orcid.org/0000-0002-6282-6583
Article History
Received: 14 September 2018
Accepted: 17 December 2018
First Online: 11 February 2019
Competing interests
: J.A.R. and C.M.S. have a financial interest in Adaptive Biotechnologies. T.F.C. and D.A.R. have received compensation from Merck as consultants on advisory boards. P.Y.W. and H.C. have received honoraria from Merck. J.F.d.G. has done consulting and/or received honoraria with Merck and Bristol-Myers Squibb. I.K.M. reports research funding from General Electric, Amgen and Lilly; advisory roles with Agios, Puma Biotechnology and Debiopharm Group; and honoraria from Roche for a presentation.